Altor BioScience
Altor BioScience is a privately owned clinical-stage biopharmaceutical company focused on treatment of cancers and viral infections using cytokine-based fusion proteins.[1][2] As of 2017 it had raised around $27.8M from investors[3] and around $20M in SBIR grants,[4] and had twelve clinical trials underway.[5] The company was spun out from Sunol in 2002 based on T cell receptor work; Sunol was previously spun out from Baxter in 1996 with the T cell receptor technology and some antibodies.[2][6]
One of its products is ALT-801, which is a fusion protein of IL-2 and a soluble T-cell receptor for p53 tumor-associated antigen (p53 TCR); ALT-801 itself attacks tumors and draws an immune response against the tumor.[2][7]
ALT-802 is a fusion protein combining immunoglobulin G and p53 TCR, and ALT-803 is a fusion protein of IL-15 and and the sushi domain of its alpha receptor, which is directly linked to the Fc region of IgG1.[2][8][9] ALT-803 was given fast track status by the FDA in 2017 and at that time, Phase III trials in bladder cancer were being prepared.[1] ALT-836 (formerly called Sunol-cH36) is a human/mouse chimeric monoclonal antibody that blocks the site on tissue factor where factor X and factor IX bind to it, and was in clinical trials to treat acute lung injury and acute respiratory distress syndrome;[10] it was originally developed at Sunol, which licensed it to Genentech, and Altor licensed it in turn.[2][11]
Patrick Soon-Shiong acquired a majority stake in Altor between 2015 and 2017, and in 2017 he attempted to have another of his companies, NantCell, acquire Altor; other shareholders objected to the terms and attempted to block the deal.[1][12] In October 2016 Altor and NantKwest, another Soon-Shiong company, had agreed to explore clinical trials combining each of ALT-801 and ALT-803 with NantKwest's cell therapies against cancer.[13]
References
- 1 2 3 Adams, Ben (June 28, 2017). "Altor shareholders revolt against Soon-Shiong buyout". FierceBiotech.
- 1 2 3 4 5 Carroll, John (May 4, 2009). "Emerging Drug Developer: Altor BioScience". FierceBiotech.
- ↑ "Altor BioScience Corp. - Company Profile -". BioCentury. Retrieved 30 June 2017.
- ↑ Pounds, Marcia Heroux (October 7, 2015). "Miramar biotech firm awarded research grant". Sun-Sentinel.com.
- ↑ Davis, Jessica (21 June 2017). "NantHealth founder Soon-Shiong hit with lawsuit over attempted takeover". Healthcare IT News.
- ↑ "Optimizing Protein Expression Speaker Biographies - PEGS 2012: Peter Rhode profile". Cambridge Healthtech Institute. Retrieved 30 June 2017.
- ↑ "ALT 801". AdisInsight. Retrieved 30 June 2017.
- ↑ "ALT 803". AdisInsight. Retrieved 30 June 2017.
- ↑ Romano, Emanuela; Margolin, Kim (2017). "18. T Cell Modulatory Cytokines". In Butterfield, Lisa H.; Kaufman, Howard L.; Marincola, Francesco M. Cancer Immunotherapy Principles and Practice. Springer Publishing Company. pp. 277–278. ISBN 9781617052736.
- ↑ Leung, K (March 21, 2013). "64Cu-1,4,7-Triazacyclononane-1,4,7-triacetic acid-p-isothiocyanatobenzyl-ALT-836". Molecular Imaging and Contrast Agent Database. PMID 23534079.
- ↑ "ALT 836". AdisInsight. Retrieved 30 June 2017.
- ↑ Montgomery, Jeff (June 21, 2017). "Altor Bioscience Suit Claims Insiders Lowballed Merger". Law360.
- ↑ Adams, Ben (October 4, 2016). "I/O pair Altor BioScience and NantKwest team up for experimental combo studies". FierceBiotech.